Related Experiment Video
Updated: Jun 19, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Prevalence of Lewy body pathology and phenotypic associations in patients with mild cognitive impairment: Evidence
Simone Baiardi1,2, Serena Caldera2, Sabina Capellari1,2
1Department of Biomedical and Neuromotor Sciences University of Bologna Bologna Italy.
Introduction:
Clinical effects and prevalence of Lewy body (LB) pathology in patients with mild cognitive impairment (MCI) remain poorly understood.
Methods:
We assessed LB pathology in 339 patients with MCI from the Italian multicenter Interceptor cohort using the cerebrospinal fluid α-synuclein seed amplification assay. Baseline assessment was followed by serial cognitive evaluations over 3 years.
Results:
LB+ participants (n = 50, 15%) were older and showed a higher frequency of parkinsonism, falls, and delirium episodes than those LB-, although these differences were not statistically significant. At follow-up, patients with biomarker evidence of Alzheimer's disease (AD), either isolated (AD+/LB-) or with concomitant LB pathology (AD+/LB+), showed the fastest cognitive decline and progression to dementia.
Discussion:
In a multicenter MCI cohort, LB pathology was associated with older age and an increased frequency of motor/psychiatric symptoms. Larger studies are needed to clarify the independent contribution of AD and LB pathologies to the MCI phenotype and clinical progression.
Insights
Lewy body (LB) pathology in mild cognitive impairment (MCI) is linked to older age and more symptoms. Alzheimer's disease (AD) and LB pathology together accelerate cognitive decline and dementia progression.
Area of Science:
- Neurology
- Neuroscience
- Pathology
Background:
- The clinical impact and prevalence of Lewy body (LB) pathology in mild cognitive impairment (MCI) are not well-established.
- Understanding LB pathology is crucial for diagnosing and managing cognitive decline.
Purpose of the Study:
- To investigate the prevalence and clinical associations of LB pathology in a cohort of patients with MCI.
- To examine the combined effects of LB pathology and Alzheimer's disease (AD) on cognitive decline in MCI.
Main Methods:
- Assessed LB pathology using the cerebrospinal fluid α-synuclein seed amplification assay in 339 MCI patients.
- Conducted serial cognitive evaluations over a 3-year follow-up period.
- Correlated LB pathology with demographic, clinical, and cognitive outcomes.
Main Results:
- 15% of MCI participants were positive for LB pathology (LB+).
- LB+ participants were older and had more frequent parkinsonism, falls, and delirium, though not statistically significant.
- Concomitant LB pathology and AD pathology (AD+/LB+) led to the most rapid cognitive decline and dementia progression.
Conclusions:
- LB pathology in MCI is associated with older age and increased motor/psychiatric symptoms.
- Combined AD and LB pathologies significantly accelerate cognitive decline in MCI.
- Further research is needed to elucidate the independent roles of AD and LB pathologies in MCI progression.
Related Concept Videos
Alzheimer Disease l: Introduction
Dementia l: Introduction
Alzheimer Disease ll: Pathophysiology
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia
The progression of dementia is generally gradual.
Interference and Decay
Interference occurs when competing memories hinder the retrieval of particular information. It can be classified into two types: proactive and retroactive interference. Proactive...
